Speaker Profile
M.D., Ph.D., Professor of Medicine, MD Anderson Cancer Ctr.
Biography
Dr. Tsimberidou is a Tenured Professor of Medical Oncology at MD Anderson. She has designed highly innovative clinical trials that have changed the standard of oncology practice. She pioneered the personalized medicine program for cancer that improved patient care and established a model for clinical trials at other institutions, nationally and internationally. She led multiple clinical trials and has published over 370 articles. She has been invited to present her work as a keynote speaker at national and international conferences. She has received many awards, including an ASCO Career Development Award. She chaired ASCO's Clinical Research Committee (2016-2017) and was appointed as a member of other committees. Because of her accomplishments in personalized medicine, she was elected a Fellow of the American Association for the Advancement of Science (FAAAS) and for her contributions to ASCO, she received the designation of Fellow of ASCO (FASCO). She is a Katherine Russell Dixie Distinguished Endowed Professor.
Talk
Concordance Analysis of DNA and RNA Profiling
In an analysis of genomic and transcriptomic alterations (tumor analysis, Tempus AI) of 253 patients with cancer treated in the IMPACT2 study, significant concordance was noted in the AR, AKT2, CDK4, CDKN2A, CDKN2B, ESR1, KRAS, and TP53 genes; and between TP53 alterations and VEGFA overexpression. High tumor transcriptional burden was associated with shorter overall survival.
Genomic Profiling Showcase:
MD Anderson Cancer Center
The mission of the University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate/graduate students, trainees, professionals, employees and the public.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Genomic Profiling Showcase will provide a 15-30 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.
